Skip to main content
C

CALIWAY BIOPHARMACEUTICALS CO., LTD. — Investor Relations & Filings

Ticker · 6919 LEI · 984500D2D587B98A7B13 TW Professional, scientific and technical activities
Open in API
Filings indexed 48 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country TW Taiwan
Listing TW 6919

About CALIWAY BIOPHARMACEUTICALS CO., LTD.

https://www.caliwaybiopharma.com

Caliway Biopharmaceuticals Co., Ltd. is a clinical-stage company specializing in the discovery and development of small-molecule therapeutics for medical aesthetics and chronic inflammatory diseases. The company focuses on high-value markets with significant unmet medical needs, utilizing unique pharmacological mechanisms to create niche products. Its lead candidate, CBL-514, is a first-in-class injectable drug designed to induce adipocyte apoptosis for non-surgical local fat reduction, cellulite, and the treatment of Dercum’s disease. Other pipeline assets include CBA-539, a long-acting injectable for pigmentation and anti-aging, and CBF-520, which targets central obesity and visceral fat reduction. Caliway aims to redefine aesthetic medicine and inflammatory disease management through innovative, non-invasive treatments that offer improved safety and efficacy over existing therapies.

Recent filings

Filing Released Lang Actions
本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之第二個 多國多中心樞紐三期臨床試驗CBL-0302申請，今日已完成加拿大 HC CTA送件
Regulatory Filings
2026-04-30 Chinese
115年第1季權益變動表
Interim / Quarterly Report Classification · 1% confidence The document is a detailed consolidated statement of changes in equity for the first quarter of the fiscal year (民國115年第1季) and the comparable prior year quarter. It contains actual quarterly financial statement data rather than an announcement or summary. This aligns with an Interim/Quarterly Report. Q1 2026
2026-04-29 English
115年第1季現金流量表
Interim / Quarterly Report Classification · 1% confidence The document text is a consolidated statement of cash flows with detailed line items for Q1 of the fiscal year (115年第1季 vs 114年第1季). It contains actual financial statements for an interim period rather than just an announcement or link to a report. This aligns with the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2026-04-29 Chinese
115年第1季綜合損益表
Interim / Quarterly Report Classification · 1% confidence The document is titled “合併綜合損益表” (Consolidated Statement of Comprehensive Income) for the first quarter of Minguo Year 115 (i.e., Q1 financial results) and contains actual financial statement line items and amounts. This is clearly part of a quarterly financial report (interim period) rather than just an announcement or summary. Therefore, it should be classified as an Interim/Quarterly Report (IR). Q1 2026
2026-04-29 Chinese
115年第1季資產負債表
Interim / Quarterly Report Classification · 1% confidence The document is a consolidated balance sheet (statement of financial position) showing detailed line‐by‐line financial data for the first quarter (115年第1季) and comparison periods. It contains actual interim financial statements (assets, liabilities, equity) for a period shorter than a full fiscal year. This fits the definition of an Interim/Quarterly Report rather than an announcement or summary. Therefore, it should be classified as IR (Interim/Quarterly Report). Q1 2026
2026-04-29 Chinese
本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之亞太二期 臨床試驗CBL-0206，今日已完成台灣TFDA IND申請
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure made on Taiwan’s Market Observation Post System (MOPS) by a listed company (6919 康霈) regarding the completion of a TFDA IND application for a Phase II clinical trial of a new drug. It is an official material event announcement under Article 10 and not an annual/interim report, earnings release, board change, dividend notice, or other specific category. It therefore falls under the general “Regulatory Filings” fallback category (Code: RNS).
2026-04-28 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.